Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors

Pharmacotherapy

Volumn 20, Issue 6 I, 2000, Pages 698-710

  Nawarskas, James J ^a   Spinler, Sarah A ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; LISINOPRIL; NIFEDIPINE; PLACEBO; TICLOPIDINE; WARFARIN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0034084475     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.7.698.35168     Document Type: Article

References (59)

1. Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy 1998;18:1041-52.
2. Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther 1998;63:79-86.
3. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999;12:784-9.
4. Hansson L, Zarchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
5. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-19.
6. Coats AJS. Enalapril, aspirin interaction [letter]. Am J Cardiol 1997;80:1122.
7. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
8. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
9. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study. Circulation 1997;96:4239-45.
10. Peterson JG, Lauer MS, Young JB, Sapp S, Califf RM, Topol EJ. Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-1 trial [abstr]. J Am Coll Cardiol 1998;31(suppl A):96A.
11. Peterson J, Lauer MS, Lincoff AM, Sapp S, Topol EJ. Evidence for a potential adverse interaction between aspirin and angiotensin converting enzyme inhibitors after percutaneous coronary angioplasty: the EPILOG trial [abstr]. J Am Coll Cardiol 1999;33(suppl A):397A.
12. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
13. The EPILOG Investigators. Platelet glycoprotein IIb-IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
14. Kingma JH, van Gilst WH, Peels CH, Dambrink J-HE, Verheugt FWA. Wielenga RP. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Eur Heart J 1994;15:898-907.
15. Oosterga M, Anthonio RL, de Kam P-J, Kingma JH, Crijns HJGM, van Gilst WH. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998;81:1178-81.
16. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-85.
17. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999;33:1920-5.
18. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
19. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-25.
20. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
21. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:658-91.
22. Guazzi M, Melzi G, Agostoni P. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;80:1572-6.
23. Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am Heart J 1999;138;254-60.
24. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril. Results of a double-blind, randomized, comparative trial. Circulation 1998;98:757-65.
25. Galatius S, Wroblewski H, Kastrup J. Does aspirin treatment influence vascular resistance and fluid filtration in patients with congestive heart failure? [letler]. Heart 1999;81:330.
26. Davie AP, Love MP, McMurray JJ. Aspirin and arachidonic acid in patients with heart failure [abstr]. Circulation 1998;98(suppl 1):1-319.
27. Harjai KJ, Nunez E, Turgut T, Newman J. The detrimental effect of combined aspirin and angiotensin converting enzyme inhibitor therapy on readmission rates in heart failure [abstr]. J Am Coll Cardiol 1999;33(suppl A):214A.
28. Katz SD, Radin M, Graves T, Hauck C, Block A, LeJemtel TH. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol 1999;34:170-6.
29. Isnard R, Baroin J-P, Drobinski G, et al. Influence of aspirin on long-term prognosis of patients with ischemic left ventricular systolic dysfunction [abstr]. Circulation 1998;98(suppl 1):1-300.
30. Aumégeat V, de Groote P, Meurice T, Millaire A, Ducloux G, Lablanche J-M. Aspirin and angiotensin converting enzyme inhibitors in 445 patients with moderate congestive heart failure [abstr]. J Am Coll Cardiol 1999;33(suppl A):214A.
31. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-5.
32. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-72.
33. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983;71:676-88.
34. 1- and thromboxane B2. J Assoc Physicians India 1995;43:597-9.
35. Polónia J, Bonaventura I, Gama G, et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995;13:925-31.
36. Smith SR, Coffman TM, Svelkey LP. Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol 1993;4:1133-9.
37. Magagna A, Abdel-Haq B, Favilla S, Taddei S, Salvetti A. Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients. Blood Press 1994;3:236-41.
38. Schmailzl KJG, Herbstleb J, Schmailzl K. Low-dose aspirin (≤ 100 mg/day) does not alter the long-term haemodynamic effects of ramipril [abstr]. Eur Heart J 1996;17(suppl):59.
39. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997;95:1930-6.
40. Moore TJ, Crantz FR, Hollenberg NK, et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981;3:168-73.
41. Schwartz D, Kornowski R, Lehrman H, et al. Combined effect of captopril and aspirin in renal hemodynamics in elderly patients with congestive heart failure. Cardiology 1992;81:334-9.
42. van Wijngaarden J, Smit AJ, de Graeff PA, et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1994;23:240-5.
43. Baur LHB, Schipperheyn JJ, van der Laarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995;73:227-36.
44. Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-19.
45. Center for Drug Evaluation and Research. FDA issues professional labeling for aspirin, October 20, 1998. http://www.fda.gov/cder/news/aspirin/aspirin_QA.htm.
46. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
47. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs. The relationships among dose, effectiveness, and side effects. Chest 1998;114(suppl):470S-88.
48. Guidelines Sub-Committee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
49. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
50. Advisory Council to Improve Outcome Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83(suppl 2A):1A-38.
51. Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers. Am Heart J 1999;138:193-7.
52. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7.
53. Poggio ED, Kottke-Marchant K, Welsh PA, et al. The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100 [abstr]. J Am Coll Cardiol 1999;33(suppl A):254A.
54. Stiegler H, Fischer Y, Niederau C, et al. Evidence for variable platelet response to low-dose ASA in patients with coronary artery disease [abstr]. J Am Coll Cardiol 1999;33(suppl A):254A.
55. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin nonresponder. A pilot study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
56. Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999;353:982-3.
57. A2 polymorphism and efficacy of aspirin. Lancet 1998;351:1253.
58. Weber A-A, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.
59. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.